Lumiliximab, also known as ST-152, represents a innovative monoclonal targeting the soluble ligand for IL -13. The molecule demonstrates significant potential in treating inflammatory disorders, https://allenvhbv734575.blognody.com/49454180/lumiliximab-a-thorough-dive-into-the-st-152-biologic